Merck KGaA in Advanced Negotiations to Acquire SpringWorks Therapeutics
Merck KGaA, a German life sciences and chemicals company, has confirmed it is in advanced discussions to potentially acquire SpringWorks Therapeutics, a U.S. biopharmaceutical company12.
SpringWorks specializes in rare diseases and cancer treatments, having recently launched its first drug, Ogsiveo, for desmoid tumors in adults23.
No legally binding agreement has been reached yet, and critical conditions still need to be met124.
SpringWorks' market value is approximately $4 billion, with its shares closing 34% higher at $54.00 on Monday following the news13.
If successful, this acquisition would be one of Merck KGaA's largest pharmaceutical deals in recent years, potentially boosting its cancer treatment pipeline68.
The potential deal comes amid increasing merger and acquisition activity in the U.S. healthcare sector, following a slowdown in 20247.
Merck KGaA has faced recent setbacks in drug trials, including halting development of a head and neck cancer drug, which may have influenced its interest in acquiring SpringWorks7.
Sources:
1. https://www.thepharmaletter.com/brief-merck-kgaa-confirms-talks-with-us-biotech-springworks
2. https://www.morningstar.com/news/dow-jones/20250211957/germanys-merck-in-talks-to-buy-springworks-therapeutics
3. https://www.investopedia.com/springworks-therapeutics-stock-soars-on-report-of-possible-acquisition-by-merck-kgaa-8789099
4. https://www.investing.com/news/stock-market-news/merck-kgaa-in-advanced-talks-to-acquire-springworks-therapeutics-93CH-3860709
6. https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-KGaA-SpringWorks-discussions-confirmed-49019429/
7. https://wtaq.com/2025/02/10/exclusive-germanys-merck-kgaa-in-talks-to-buy-us-biotech-firm-springworks-sources-say/
8. https://www.marketscreener.com/quote/stock/MERCK-KGAA-436395/news/Merck-confirms-talks-on-takeover-of-US-biotech-company-49014573/